Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.
Chris Lange Making the move for a secondary offering after a stock has jumped massively is one way for companies to literally cash in on their recent success.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Tuesday morning include American Electric Power, Broadcom, Ford, General Motors, JD.com, Sarepta Therapeutics and Valeant Pharmaceuticals.
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, AT&T, Autodesk, Bluebird Bio, Monsanto and Sarepta Therapeutics.
Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy.
Chris Lange These four biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the past year, offering aggressive accounts the best entry points in…
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen more than its fair share of volatility in the market of late. Now shares are surging after it has reached a compromise with the U.S.…
Jon C. Ogg The top analyst upgrades, downgrades and initiations seen on Tuesday morning include First Data, General Electric, Sarepta Therapeutics, Western Digital, Walgreens Boots Alliance and Zillow.
Sarepta Therapeutics and Globalstar are among the companies that punished shareholder the most this past week.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade from Janney Montgomery Scott.
Chris Lange Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Apple, Twitter and other companies punished shareholders last week, and analysts expect more earnings disappointments going forward.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital and Whiting Petroleum.
